期刊文献+

粪肠球菌噬菌体vB_E.faecalis_IME196的生物学特性及其全基因组分析 被引量:9

Characterization and complete genome sequence analysis of Enterococcus faecalis bacteriophage v B_E. faecalis_IME196
原文传递
导出
摘要 【目的】从医院污水中分离一株能裂解多耐药粪肠球菌的噬菌体,分析该噬菌体的生物学特性,并进行全基因组测序和分析,为治疗和控制多耐药粪肠球菌感染提供基础。【方法】以耐药粪肠球菌为宿主,从医院污水分离噬菌体,双层平板法检测噬菌体效价、最佳感染复数(MOI)和一步生长曲线,纯化后负染法电镜观察噬菌体形态;蛋白酶K/SDS法提取噬菌体全基因组,酶切处理后琼脂糖凝胶电泳分析,使用Ion Torrent测序平台进行噬菌体全基因组测序,测序后进行噬菌体全基因组序列组装、注释、进化分析和比较分析。【结果】分离到一株粪肠球菌噬菌体,命名为v B_E.faecalis_IME196(IME196);其最佳感染复数为0.01,一步生长曲线显示IME196的潜伏期为30 min,暴发量为50 PFU,电镜观察该噬菌体为长尾噬菌体,结合BLASTp分析确定其属于尾病毒目长尾噬菌体科,基因测序表明,噬菌体IME196核酸类型为DNA,基因组全长为38 895 bp,G+C含量为33.9%。【结论】分离鉴定一株粪肠球菌噬菌体,进行了全基因组测序和分析,为以后预防和控制粪肠球菌的感染提供了一个新的途径,为噬菌体治疗多重耐药细菌奠定了基础。 [Objective] We isolated a novel virulent bacteriophage specifically infecting antibiotics-resistant Enterococcus faecalis from hospital sewage, to study its morphology and to analyze its genome so as to provide basis for treatment and infection control of antibiotics-resistant E. faecalis. [Methods] We used E. faecalis as the host to isolate phage from raw sewage from the sewage treatment center of a hospital. Transmission electromicroscopy, optimal multiplicity of infection(optimal MOI) and one-step growth curve were conducted. The genome DNA was extracted and sequenced by high-throughput sequencing technology. The feature of whole genome, and evolutionary relationship were analyzed. [Results] A lytic bacteriophage designated as v B_E. faecalis_IME196(IME196) was isolated. The optimal multiplicity of infection(optimal MOI) of IME196 is 0.01. One-step growth curve shows that IME196 has a burst size of 50 PFU and a latent period of 30 min. The genome of IME196 is a 38 895 bp in length, linear, terminally non-redundant double-stranded DNA and has a G+C content of 33.9%. [Conclusion] Isolation and characterization of a lytic Enterococcus faecalis phage will help supply a new way to prevent and control the infection of E. faecalis, and laid a foundation to the treatment of multiple drug resistant bacteria in the future.
出处 《微生物学通报》 CAS CSCD 北大核心 2016年第9期2040-2048,共9页 Microbiology China
基金 科技重大专项“十二五”实施计划项目(No.2013ZX10004-605,2013ZX10004-217,2013ZX10004-607,2011ZX10004-001) 国家高技术研究发展计划项目(863计划)(No.2014AA021402,2012AA022-003) 国家自然科学基金项目(No.81572045)~~
关键词 噬菌体 粪肠球菌 生物学特性 全基因组测序 基因组分析 Phage Enterococcus faecalis Biological characteristics Whole genomic sequencing Genomics
  • 相关文献

参考文献4

二级参考文献38

  • 1萨姆布鲁克 J,拉塞尔 D W.分子克隆实验指南[M].3版.林培堂,译.北京:科学出版社,2002.
  • 2Klare I, Witte W, Wendt C, et al. Vancomycin-resistant en-terococci(YRE): recent results and trends in development ofantibiotic resistance] [J]. Bundesgesundheitsblatt Gesundheits-forschung Gesundheitsschutz, 2012,55(11-12):1387-1400.
  • 3Karki S, Houston L, Land G, et al. Prevalence and risk fac-tors for VRE colonisation in a tertiary hospital in Melbourne,Australia: a cross sectional study[J]. Antimicrob Resist InfectControl, 2012,1(1):31.
  • 4Sulakvelidze A. Bacteriophage: a new journal for the mostubiquitous organisms on earth[J]. Bacteriophage, 2011,1(1):1-2.
  • 5Sulakvelidze A, Alavidze Z, Morris J J. Bacteriophage therapy[J]. Antimicrob Agents Chemother, 2001,45(3):649-659.
  • 6Clark J R, March J B. Bacteriophages and biotechnology: vac-cines, gene therapy and antibacterials[J]. Trends Biotechnol,2006,24(5):212-218.
  • 7Payne R J, Phil D, Jansen V A. Phage therapy: the peculiarkinetics of self-replicating pharmaceuticals[J]. Clin PharmacolTher,2000,68(3):225-230.
  • 8Thongkoom P, Kanjanahareutai S, Chantrakooptungool S, et al.Vancomycin-resistant enterococci(VRE) isolates isolated in Ra-javithi Hospital between 1999 and 2009[J]. J Med AssocThai, 2012,95(Suppl 3):S7-S15.
  • 9Matsuzaki S, Rashel M,Uchiyama J, et al. Bacteriophage ther-apy: a revitalized therapy against bacterial infectious diseases[J]. J Infect Chemother, 2005,11(5):211-219.
  • 10Abedon S T, Kuhl S J, Blasdel B G, et al. Phage treatmentof human infections[J]. Bacteriophage, 2011,1(2):66-85.

共引文献46

同被引文献66

引证文献9

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部